Phase 2 Trials | Selective NaV1.8 inhibitor, VX-548, shows potential in acute postoperative pain management

Selective Inhibition of NaV1.8 with VX-548 for Acute Pain – New England Journal of Medicine (link to abstract – $ for full-text)

Video Summary: Selective Inhibition of NaV1.8 for Acute Pain | NEJM

Commentaries:

High-Dose VX-548 Reduces Acute Pain Post-Surgery – HCP Live

High-Dose VX-548 Reduces Acute Pain Over 48 Hours – HealthDay

Commentary on Twitter

Original Article: Selective Inhibition of NaV1.8 with VX-548 for Acute Pain https://t.co/ogmEx6FNKo#surgery pic.twitter.com/0FpipA1xey

— NEJM (@NEJM) August 5, 2023